Alnylam Pharmaceuticals, Inc. (ALNY) Reports Q3 Loss of 31c/Share
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $266.11 +0.61%
EPS Growth %: -39.0%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -39.0%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported Q3 EPS of ($0.31), $0.04 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $20.8 million versus the consensus estimate of $20.51 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
- Torrid Holdings Inc. (CURV) Tops Q2 EPS by 8c; Offers Guidance
- Ambarella (AMBA) Tops Q2 EPS by 1c; offers guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
